ロード中...

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells

BACKGROUND: Due to the frequent dysregulation of the PI3K/AKT/mTOR signaling pathway, mTOR represents a suitable therapeutic target in hepatocellular carcinoma (HCC). However, emerging data from clinical trials of HCC patients indicate that mTOR inhibition by RAD001 (Everolimus) alone has only moder...

詳細記述

保存先:
書誌詳細
主要な著者: Grabinski, Nicole, Ewald, Florian, Hofmann, Bianca T, Staufer, Katharina, Schumacher, Udo, Nashan, Björn, Jücker, Manfred
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2012
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3545733/
https://ncbi.nlm.nih.gov/pubmed/23167739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-85
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!